MCMP%20408%20Midterm%202009%20key

MCMP%20408%20Midterm%202009%20key - Name: _KEY_ MCMP 408...

Info iconThis preview shows pages 1–4. Sign up to view the full content.

View Full Document Right Arrow Icon
Name: _____ KEY __________________ MCMP 408 MIDTERM EXAM MARCH 5, 2009 100 POINTS Directions 1. There are 50 multiple choice questions. Select the ONE most correct answer and place all answers on the Scantron sheet provided using a #2 pencil. 2. PLEASE KEEP SCANTRON SHEETS COVERED AT ALL TIMES. 3. DO NOT LOOK AROUND DURING THE EXAM. ANY SUSPICIOUS BEHAVIOR WILL RESULT IN INDIVIDUALS BEING MOVED TO THE FRONT OF THE ROOM. 4. Results from the midterm exam will be posted on the class Blackboard by Tuesday, March 10. 5. At the end of the exam, turn in BOTH your question packet and the Scantron Sheet.
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
1. In acetaminophen-induced liver toxicity: a. Glutathione metabolism by CYP450 is induced b. Toxic metabolites are generated by CYP2E1 c. Liver N-acetylcysteine is depleted d. All of the above 2. Rapid acetylators of hydralazine are prone to auto-immune-like disease: a. True b. False 3. Which of the following is a potent inducer of S-warfarin metabolism: a. Rifampin b. Ketoconazole c. N-acetylcysteine d. Grapefruit juice 4. Succinlycholine apnea is associated with: a. Genetic polymorphism of CYP2D6 b. Overexpression of 2-N-acetyltransferase c. Expression of an atypical cholinesterase d. A predisposition to drug-induced systemic lupus 5. Teratogenesis is classified as a reproductive toxicity: a. True b. False 6. Which of the following would inhibit MPTP toxicity: a. Selegiline b. Grapefruit juice c. Ketoconazole d. R-Warfarin 7. Pharmacogenomic analysis can be used to: a. Detect inter-individual variation in drug responses b. Detect multiple forms of drug molecular structure c. Predict drug metabolism patterns d. All of the above e. A and C above
Background image of page 2
8. Phase 4 drug evaluation is best described as: a. Pre-marketing surveillance b. Post-marketing surveillance c. Preclinical efficacy evaluation d. Postclinical drug metabolism analysis 9. Thalidomide is: a. A potent reproductive toxicant b. A potent inducer of folic acid metabolism c. A potent mutagen d. None of the above 10. Toxicogenomic analysis of a new drug candidate: a. Is conducted as part of the post-marketing surveillance b. Is a finger print analysis of teratogensis c. Is a genomic finger print analysis of potential toxic biomarkers d. Will likely replace animal studies of new drugs e. All of the above 11. The “hypersentive period” of human prenatal development to a teratogen is: a. Week 1-2: Zygote phase b. Week 3-12: Organogenetic phase c. Week 20-30: Developmental phase d. Week 45-50: Reproductive phase 12. Codeine undergoes bioactivation by CYP2D6. In individuals expressing 0 (zero) functional CYP2D6 genes, normal therapeutic doses of codeine would likely: a. Be toxic due to accumulation of high blood levels
Background image of page 3

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 4
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 03/11/2010 for the course MCMP 123 taught by Professor -- during the Spring '10 term at Purdue University-West Lafayette.

Page1 / 9

MCMP%20408%20Midterm%202009%20key - Name: _KEY_ MCMP 408...

This preview shows document pages 1 - 4. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online